Superworth

GENELUX revenue GNLX

Sales by quarter and over the last twelve months, from 2022.

Last 12 months, to Dec 31, 2024
$8K
Latest quarter, Q4 FY24
$0
Fiscal year 2024
$8K
−95% on the year before

GENELUX's revenue was $8K over the twelve months to Dec 31, 2024, down 95% on a year earlier.

In its latest quarter, Q4 FY24, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$8K−95%
FY2023$170Kn/a
FY2022n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY24$0n/a$8K
Q3 FY24$0n/a$8K
Q2 FY24$0n/a$8K
Q1 FY24$8K−95%$8K
Q4 FY23$0−100%$170K
Q3 FY23$0−100%$238K
Q2 FY23$0n/a$11.2M
Q1 FY23$170Kn/an/a
Q4 FY22$68Kn/an/a
Q3 FY22$11Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest GENELUX's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
GNLXGENELUXn/m
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
Peer median$316.7M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on GENELUX

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.